

Section 1 - Conflict Minerals Disclosure

Item 1.01 - Conflict Minerals Disclosure and Report

Endologix, Inc. (the “Company,” “we,” “us,” or “our”) prepared and filed this Form SD pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2017 to December 31, 2017. A copy of our Conflict Minerals Report is attached as Exhibit 1.01 to this Form SD, and is publicly available on our website at www.endologix.com (Investor Relations - Corporate Governance). The information contained on our website is not incorporated by reference into this Form SD or the Conflict Minerals Report and should not be considered part of this Form SD or the Conflict Minerals Report.

We conducted an analysis and evaluation of all of our current products and our supply chain to determine whether such products contain conflict minerals, as defined by Rule 13p-1, and determined that certain products we manufacture or contract to be manufactured for us may contain conflict minerals. In accordance with Rule 13p-1, we performed a reasonable country of origin inquiry to determine the source and chain of custody of the potential conflict minerals contained within our products. Our Conflict Minerals Report attached as Exhibit 1.01 hereto describes the results of our reasonable country of origin inquiry and our due diligence process.

Item 1.02 - Exhibit

The Conflict Minerals Report contemplated by Item 1.01 is filed as Exhibit 1.01 to this Form SD.

Section 2 - Exhibits

Item 2.01 - Exhibits

The following exhibit is filed as part of this Form SD.

Exhibit 1.01 - Conflict Minerals Report of Endologix, Inc. for the calendar year ended December 31, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENDOLOGIX, INC.

Date: May 31, 2018 /s/ Vaseem Mahboob
Vaseem Mahboob,
Chief Financial Officer